Results 201 to 210 of about 187,379 (300)

Customer Communications Management (CCM) as a Competitive Advantage in Insurance: AI-Driven Personalization, Omni-Channel Engagement, and Customer Retention [PDF]

Sravanthi Mareddy
openalex   +1 more source

Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract Central serous chorioretinopathy (CSC) is a chorioretinal disease characterised by serous subretinal fluid (SRF) in the macula, resulting in sudden central vision loss. It predominantly affects working‐age adults, particularly men aged 30 to 60 years.
I. Made Ferdiko Hutamadella, Emil Ørnberg, Mark P. Breazzano, Lasse Jørgensen Cehofski, Chui Ming Gemmy Cheung, Kristina Pfau, M. Cem Sabaner, Lorenzo Ferro Desideri, Camiel J. F. Boon, Yousif Subhi, Elon H. C. van Dijk   +10 more
wiley   +1 more source

Comprehensive Conservative Management as Rescue Therapy After Haemodialysis Failure: Two Case Reports. [PDF]

Clin Pract
Martino FK, Martella A, Fioretti F, Cattarin L, Stefanelli FL, Nalesso F.   +5 more
europepmc   +1 more source

Capsule Endoscopy in a Patient with an Implanted CCM System and an Implantable Defibrillator [PDF]

, 2011
Florian Streitner, Nina Schoene, Martin Borggrefe, Jürgen Kuschyk   +3 more
openalex   +1 more source

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source

Safety and Efficacy of Stroke Thrombolysis for Patients with Cerebral Cavernous Malformations: Literature Review and Nationwide Cohort Study. [PDF]

NeuroSci
Chen H, Laursen RK, McIntyre MK, Jain M, Salim HA, Lakhani DA, Malhotra A, Gandhi D, Colasurdo M.   +8 more
europepmc   +1 more source

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX‐SEMA 2.4 mg, an Italian real‐world study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate real‐world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short‐term efficacy. Materials and Methods This retrospective study included obese patients treated with the weekly injectable semaglutide.
Simone Pampanelli, Stefano Terzoni, Paola Pantanetti, Chiara Di Loreto, Alessio Mazzieri, Giovanni Cangelosi, Sara Alberti, Cristina Badiali, Ilenia Grandone, Sara Migliarelli, Maria Grazia Castagna, Mariaclaudia Cerrai Ceroni, Nicoletta Benenati   +12 more
wiley   +1 more source

Navigating the Lead Paradox: Successful Co-Implantation of Cardiac Contractility Modulation Device and a Micra Leadless Pacemaker. [PDF]

J Cardiovasc Electrophysiol
Pavani G, Garrone P, Varalda G, Previti A, Bianco M, Chinaglia A.   +5 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Effects of the continuous care model on the lifestyle of adolescents with type 1 diabetes in Tehran clinics- an experimental study. [PDF]

BMC Endocr Disord
Shiranian S, Roshan FS, Farahani MF.
europepmc   +1 more source